Bio-Rad's Q3 2025 results showcase stable revenue amidst macro challenges, highlighted by strong performance in process chromatography and disciplined cost management that yielded improved operating margins.

• Q3 revenue was approximately $653 million, reflecting a 0.5% year-over-year increase but a 1.7% decline on a currency-neutral basis due to soft demand in Life Sciences and Clinical Diagnostics segments.
• The Clinical Diagnostics segment saw a slight rise to $391 million, impacted by lower diabetes testing reimbursement rates in China, while the Life Science segment remained flat at $262 million.
• Gross margin decreased to 52.6% from 54.8% year-over-year, primarily driven by higher material costs; however, operating income increased to approximately $65 million due to improved margin management.
• Bio-Rad advanced its Droplet Digital PCR strategy and secured partnerships with Gencurix and Biodesix to expand its diagnostic testing capabilities, signaling potential growth avenues in the oncology space.
• Ongoing budgetary constraints in academic research and biotech funding persist, extending the sales cycles for new products, though customer interest in new QX platforms is promising.